rogressive hemifacial atrophy, or Parry-Romberg syndrome, is a rare disorder characterized by gradual, unilateral atrophy of soft tissue in the face within regions innervated by branches of the trigeminal nerve. 1 One widely used classification system, attributed to Iñigo et al., 2 denotes the disease as mild if atrophy is limited to one trigeminal nerve branch, or moderate if it involves two branches. Severe cases are either those involving all three trigeminal nerve branches, or if there exists any bony involvement. 2,3 Degeneration may persist over the course of 2 to 20 years, until spontaneous quiescence, with an earlier age of onset associated with more severe bony involvement and poorer outcomes, especially in pediatric patients. [4][5][6][7] Although treatment with agents such as steroids, methotrexate, antimalarials, and retinoids may be initiated early on during the disease process in an attempt to curb progression, 8 softtissue reconstruction is often necessary for restoration of form and function. 4,9 Although there exists a